Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib plus azacitidine safety study in newly diagnosed IDH1-mutant AML patients ineligible for intensive chemotherapy
NL-OMON59845Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ivosidenib and azacitidine in acute myeloid leukemia (AML), sponsored by Servier. Primary endpoints: Adverse events, Clinical laboratory anomalies assessed as adverse events and 2 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
ivosidenibazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON59845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59845.